EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ANGPTL3 deficiency impairs lipoprotein production and produces adaptive changes in hepatic lipid metabolism

Kendall H Burks, Yan Xie, Michael Gildea, In-Hyuk Jung, Sandip Mukherjee, Paul Lee, Upasana Pudupakkam, Ryan Wagoner, Ved Patel, Katherine Santana, Arturo Alisio, Ira J Goldberg und 4 weitere

Journal of Lipid Research · 2024

DOI: 10.1016/j.jlr.2024.100500 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Lipid Research, 2024. Verfasst von Kendall H Burks und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, Center for Cardiovascular Research, Washington University School of Medicine, Saint Louis, MO, USA. Hauptthemen laut MEDLINE: Angiopoietin-Like Protein 3, Lipid Metabolism. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Angiopoietin-like protein 3 (ANGPTL3) is a hepatically secreted protein and therapeutic target for reducing plasma triglyceride-rich lipoproteins and low-density lipoprotein (LDL) cholesterol. Although ANGPTL3 modulates the metabolism of circulating lipoproteins, its role in triglyceride-rich lipoprotein assembly and secretion remains unknown. CRISPR-associated protein 9 (CRISPR/Cas9) was used to target ANGPTL3 in HepG2 cells (ANGPTL3-/-) whereupon we observed ∼50% reduction of apolipoprotein B100 (ApoB100) secretion, accompanied by an increase in ApoB100 early presecretory degradation via a predominantly lysosomal mechanism. Despite defective particle secretion in ANGPTL3-/- cells, targeted lipidomic analysis did not reveal neutral lipid accumulation in ANGPTL3-/- cells; rather ANGPTL3-/- cells demonstrated decreased secretion of newly synthesized triglycerides and increased fatty acid oxidation. Furthermore, RNA sequencing demonstrated significantly altered expression of key lipid metabolism genes, including targets of peroxisome proliferator-activated receptor α, consistent with decreased lipid anabolism and increased lipid catabolism. In contrast, CRISPR/Cas9 LDL receptor (LDLR) deletion in ANGPTL3-/- cells did not result in a secretion defect at baseline, but proteasomal inhibition strongly induced compensatory late presecretory degradation of ApoB100 and impaired its secretion. Additionally, these ANGPTL3-/-;LDLR-/- cells rescued the deficient LDL clearance of LDLR-/- cells. In summary, ANGPTL3 deficiency in the presence of functional LDLR leads to the production of fewer lipoprotein particles due to early presecretory defects in particle assembly that are associated with adaptive changes in intrahepatic lipid metabolism. In contrast, when LDLR is absent, ANGPTL3 deficiency is associated with late presecretory regulation of ApoB100 degradation without impaired secretion. Our findings therefore suggest an unanticipated intrahepatic role for ANGPTL3, whose function varies with LDLR status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiopoietin-Like Protein 3Lipid MetabolismAngiopoietin-like ProteinsApolipoprotein B-100LipoproteinsLiverTriglycerides

Stichwörter der Autor:innen

LDL/metabolismPPARsVLDLapolipoproteinsdyslipidemiaslipase/endothelialtriglycerides

Substanzen

Angiopoietin-Like Protein 3Angiopoietin-like ProteinsApolipoprotein B-100LipoproteinsTriglyceridesANGPTL3 protein, human

Autor:innen und Institutionen

  • Division of Cardiology, Department of Medicine, Center for Cardiovascular Research, Washington University School of Medicine, Saint Louis, MO, USA.
  • Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.
  • Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.
  • Division of Nutritional Science and Obesity Medicine, Department of Medicine, Center for Human Nutrition, Washington University School of Medicine, Saint Louis, MO, USA.
  • Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.
  • Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA. Electronic address: nod@wustl.edu.

Förderung

  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • NIGMS NIH HHS
  • NHGRI NIH HHS
  • Regeneron Pharmaceuticals
  • National Institutes of Health
  • American Heart Association
  • Foundation for Barnes-Jewish Hospital

Zitieren

APA

Burks, K. H., Xie, Y., Gildea, M., Jung, I. H., Mukherjee, S., Lee, P., Pudupakkam, U., Wagoner, R., Patel, V., Santana, K., Alisio, A., Goldberg, I. J., Finck, B. N., Fisher, E. A., Davidson, N. O., & Stitziel, N. O. (2024). ANGPTL3 deficiency impairs lipoprotein production and produces adaptive changes in hepatic lipid metabolism. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2024.100500

Vancouver

Burks KH, Xie Y, Gildea M, Jung IH, Mukherjee S, Lee P, et al. ANGPTL3 deficiency impairs lipoprotein production and produces adaptive changes in hepatic lipid metabolism. Journal of Lipid Research. 2024. doi:10.1016/j.jlr.2024.100500

BibTeX
@article{Burks2024,
  author = {Burks, Kendall H and Xie, Yan and Gildea, Michael and Jung, In-Hyuk and Mukherjee, Sandip and Lee, Paul and Pudupakkam, Upasana and Wagoner, Ryan and Patel, Ved and Santana, Katherine and Alisio, Arturo and Goldberg, Ira J and Finck, Brian N and Fisher, Edward A and Davidson, Nicholas O and Stitziel, Nathan O},
  title = {ANGPTL3 deficiency impairs lipoprotein production and produces adaptive changes in hepatic lipid metabolism},
  journal = {Journal of Lipid Research},
  year = {2024},
  doi = {10.1016/j.jlr.2024.100500}
}
Kostenlos starten →